Amarin news from FierceBiotech
NewsALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
> Ambrilia Biopharma reported positive 24-week Phase III top-line results for prolonged-release formulation of Octreotide. Read more...
ALSO NOTED: Phyton cuts staff; Alzheimer's: A new indication for Enbrel?; and much more...
> According to research released today, the anti-rheumatoid arthritis med Enbrel has shown an amazing ability to rehabilitate Alzheimer's patients. Read more...
| Press ReleasesPRESS RELEASE: Amarin Corporation to Buy Privately Held Ester Neurosciences for up to $17M Amarin Corporation to Buy Privately Held Ester Neurosciences for up to $17M LONDON, December 5 -- Amarin Corporation today announced that the Company has: - Signed an agreement to acquire Ester Read more... |
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends